Skip to content

The Lone Star Bleeding Disorders Foundation is pleased to announce the Matthew Thomas Memorial Academic Scholarship Fund. 

To serve the bleeding disorders community of South Texas, the Lone Star BDF will award up to four $2,500 Academic Scholarships for the 2023-2024 school year.

To be eligible for the Matthew Thomas Memorial Academic Scholarship, students must be directly affected with an inherited bleeding disorder, or an immediate family member of someone with a bleeding disorder (parent/guardian/sibling/child of) and pursuing a degree from an accredited post-secondary University, College, or Junior College.  They do not have to be first-year students.  This scholarship is open to anyone pursuing a degree.

 

Along with a completed scholarship application, qualified applicants must provide documentation of post-secondary enrollment, high school/college transcripts, letters of recommendation, and personal essay.  A person may only receive a scholarship once.


Download PDF Application  or  Fill Out Form Online


Matthew Thomas Memorial Academic Scholarship Checklist

Submit completed application and requested documents on our website www.lonestarbleedingdisorders.org under the Resources Tab by April 30th, 2024

You may also send printed application and documents, postmarked by April 30th, 2024 to

Lone Star Bleeding Disorders Foundation

ATTN:  Scholarship Committee

5600 Northwest Central Suite 140

Houston, TX 77092

Or email to Heidi Hensley

Be sure to include:
  •  
    • Completed Application
    • High-school or college transcripts
    • Documentation of post-secondary enrollment
    • Personal Essay
    • Two letters of recommendation

News from HFA

  • Advocacy News: May 2024

    Word from Washington Federal Agencies CMS extends waiver flexibilities, reporting requirements for Medicaid “unwinding” redeterminations According to the latest KFF Medicaid Unwinding Enrollment Tracker,  nearly 23 million Americans have lost Medicaid coverage since states were allowed to resume eligibility verifications following the COVID-19 public health emergency (PHE). Nearly 70 percent of Medicaid terminations continue to The post Advocacy News: May 2024 appeared first on Hemophilia Federation of America.

  • Leading Advocacy Organizations Celebrate Federal Rule Strengthening Protections Against Disability Discrimination 

    The Bleeding Disorders Substance Use and Mental Health Access Coalition (BD SUMHAC), National Bleeding Disorder Foundation (NBDF) and Hemophilia Federation of America (HFA) are pleased to share that after advocacy from the bleeding disorders community, the U.S. Department of Health and Human Services (HHS), through its Office for Civil Rights (OCR), finalized a new rule The post Leading Advocacy Organizations Celebrate Federal Rule Strengthening Protections Against Disability Discrimination  appeared first on Hemophilia Federation of America.

  • Advocacy News: April 2024

    Word from Washington After one year, Medicaid coverage losses during “unwinding” continue to surpass worst fears According to the latest KFF Medicaid Unwinding Enrollment Tracker, more than 21 millionAmericans have lost Medicaid coverage during the first year after states were allowed to resume eligibility verifications following the COVID-19 public health emergency. There remains wide variation The post Advocacy News: April 2024 appeared first on Hemophilia Federation of America.

  • May is Hepatitis Awareness Month

    In 2001, the Centers for Disease Control and Prevention designated the month of May as Hepatitis Awareness Month to bring awareness and attention to those living with viral hepatitis. In the 1980s and ’90s, thousands of people with hemophilia contracted HIV and hepatitis C (HCV) from the contaminated blood supply transmitted by clotting factor products. The post May is Hepatitis Awareness Month appeared first on Hemophilia Federation of America.

  • FDA Approves One-Time Gene Therapy for Adults with Hemophilia B

    From Pfizer: Pfizer Inc. announced that the US Food and Drug Administration has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing The post FDA Approves One-Time Gene Therapy for Adults with Hemophilia B appeared first on Hemophilia Federation of America.